Recent Updates — GLPG

Lakefront Biotherapeutics completed the sale of its early-stage cell therapy pipeline, including multi-targeting and armed CAR-T constructs, to Armed Cell Therapeutics BV. The transaction includes an upfront payment of €8 million and potential milestone payments totaling up to $230 million, along with a low-single-digit royalty on future sales. This divestiture substantially completes the company's previously announced wind-down of legacy cell therapy activities. Lakefront Biotherapeutics is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.